#ACR21 #Abstr0454 Mortality rate in #lupus nephritis ⬇️by 26% from 1999-2019👏. BUT, racial and residence disparities were concerning; worse in Black, Hispanic, Asian, AI/AN vs White and in large central and medium metro. Residential matters! @RheumNow https://t.co/33vN39acuL https://t.co/XMwN2hXJn7

• Lupus Nephritis Mortality in the United States, 1999-2019: Profound Disparities…

Race/ethnicity and residence were independent risk factors for LN mortality which was higher in: ➡️Black patients ➡️Those living in central metro areas #ACR21 Abst#0454 @RheumNow

#ACR21 Abst#0456. Fxnal connectivity, ⬆️ blood-brain barrier (BBB) leakage & cognitive impairment (CI) in SLE ⭐️SLE pts ⬆️♀️, older, caucasian, ⬇️ edu than controls ⭐️CI in longer disease, APS ▶️ SLE CI:⬇️Brain-wide connections, BBB permeability https://t.co/fen9OYhWhC @Rheumnow https://t.co/DMQfWCqUhh

• https://bit.ly/3wlgGH3

Functional MRI eval neuro-connectivity in 78 SLE pts Cognitive impairment occurred in 48%; pts had: 👉longer disease duration 👉likely +LAC 👉abnormal fMRI 👉>blood brain barrier permeability #ACR21 #Plenary Abstr# 0456 @rheumnow https://t.co/WI5CD73rvM

How about lipoprotein a as a potential biomarker for poor renal outcomes in #lupus? Results of this study by Dr @CaoilfhionnMD and her group show that ⬆Lp(a) is strongly associated w/ proteinuria, ⬇ eGFR and ⬆PGA. Interesting🤓 @RheumNow #ACR21 abs0327 https://t.co/MLgJ1tPJMp

#ACR21 Many faces of cell death Netosis in APS and #SLE NETs and APS 🕸️NETs are prothrombotic🕸️ https://t.co/FG3VNbQPzh

Plenary I 0454 LN mortality in the US & disparities using CDC WONDER data 1999-2019 "LN mortality exhibited profound disparities by race/ethnicity and place of residence" https://t.co/UtMzaiL14D #ACR21 https://t.co/C3fuq8anvR

• Lupus Nephritis Mortality in the United States, 1999-2019: Profound Disparities…

Dr. Petri et al showed transition between lupus anticoagulant (-) to (+), (+) to (-), and (+) or (-) to thrombosis could be estimated by multistate Markov model. #ACR21 Abst#0076 @RheumNow https://t.co/oIvbak4lV4

Machine learning predicted lupus nephritis in #SLE patients in real world data #ACR21 @RheumNow #abst0324 https://t.co/67HBT7F2GO

Don't wait! DR. Petri wants us to change paradigm of how we treat aggressive lupus nephritis: early, aggressive, and multimodal. Does not matter if you add on VCS or BLMB, just don't treat LN with MMF monotherapy. #ACR21 #GreatDebate @rheumnow https://t.co/ebSiic095h

"I don't want rheumatologist only use BLMB and nephrologist using only VCS." - Dr. M Petri on how we should work together with nephrologists on managing lupus nephritis. (She did give a final dig & added "BLMB can be used with any GFR") #ACR21 #GreatDebate @rheumnow

#GreatDebate: add on BLMB vs. VCS to MMF for LN Dr. Petri argues for BLMB b/c: 👉cost is less 👉better adherance 👉not good for class V 👉voclosporin had greater nephrotoxicity 👉insuff data in pregnancy, but not contraindicated like VSC #ACR21 @rheumnow https://t.co/mk2eXwkxcG

#ACR21 Great Debate Dr. Brad Rovin: Voclosporin: Combo with MMF is effective pts of diverse racial and ethnic backgrounds. ⭐️Big plus for a disease with large healthcare disparity issues @Rheumnow https://t.co/rMpCRPLLGQ

KL-6, Anti-Ku, anti-CENPB were assoc'd w/ #myositis &/or ILD in #lupus patients accdg to this study by Dr. T Cotton et al. This may help identify patients at risk for developing such. @RheumNow #ACR21 abs0330 https://t.co/p0uxBOTLZm

Great Debate on Voclosporin vs. Belimumab in Lupus Nephritis therapy. Dr. Petri argues Belimumab has less potential AE including infections, cardiovascular risk, malignancy potential. No drug-drug interactions. What would you choose? #ACR21 #ACRBest @RheumNow https://t.co/FywUp3zCj2